Neuren Pharmaceuticals Limited reported earnings results for the half year ended June 30, 2023. For the half year, the company reported revenue was AUD 64.4 million compared to AUD 0.3 million a year ago. Net income was AUD 47.8 million compared to net loss of AUD 7.1 million a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
20.27 AUD | -6.33% | -15.44% | -18.82% |
May. 28 | Transcript : Neuren Pharmaceuticals Limited - Shareholder/Analyst Call | |
May. 27 | Neuren Phase 2 Trial Shows Significant Improvements in Pitt Hopkins Syndrome | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.82% | 1.83B | |
+40.73% | 739B | |
+32.23% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+14.23% | 240B | |
+9.19% | 210B | |
-5.52% | 206B | |
+6.17% | 164B |
- Stock Market
- Equities
- NEU Stock
- News Neuren Pharmaceuticals Limited
- Neuren Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended June 30, 2023